Financial Daily from THE HINDU group of publications
Thursday, Jul 18, 2002

News
Features
Stocks
Port Info
Archives

Group Sites

Industry & Economy - Pharmaceuticals


3 IISc proteins for Cadila, Shantha Biotech

Madhumathi D.S.

BANGALORE, July 17

THREE recombinant therapeutic proteins are in the making at the Indian Institute of Science, Bangalore, and are shortly to be transferred to two domestic pharma majors for further trials.

Two of them, the human chorionic gonadotropin (hCG) and the follicle stimulating hormone (FSH), will be used to treat infertility in men and women. These are being acquired by Cadila Pharmaceuticals, which has part sponsored this research project at the institute's Molecular Reproduction, Development & Genetics Department. The hCG is used in in vitro fertilisation cases.

The third protein, the human growth hormone, which can form a therapy for dwarfism and anti-ageing, is to be transferred to Shantha Biotechnics of Hyderabad.

Purification and characterisation of the proteins is going on, according to Dr R.R.Dighe, Associate Professsor at the department, who has been researching in therapeutic proteins.

Dr Dighe says drugs based on the recombinant hormones would be far more affordable than the ones that are being imported. For growth deficiency, for example, the current imported therapies which have to be taken over 4-5 years could cost a prohibitive Rs 3 lakh a year.

However, the three recombinant proteins would have to go through "another big exercise" before they became products. These would have to be scaled up, after which the industry would have to conduct toxicological studies and clinical trials. "There is still a lot of work to go before doctors can prescribe them," he told Business Line.

The gonadotropins using yeast instead of animals like sheep are an offshoot of Dr Dighe's larger and ongoing research in molecular endocrinology.

The Ahmedabad based Cadila has also set up a Rs 2-crore R&D centre on the campus for independent research its first in outside and is also supporting a handful of projects at the institute.

Called Dhanvantari Kshetra, it is the first pharma lab on the campus and also Cadila's only R&D unit outside Ahmedabad.

Send this article to Friends by E-Mail

Stories in this Section
Anti-dumping probe on Chinese silk imports


Clouds over crop area — Kharif sowing toll heaviest for soya
Focus on Pondicherry — Resourceful plans
`Monsoon delay may hit rural markets'
Improving the industrial climate
IBRD approves $108-m credit for forest project in AP
Bengal seeks IBRD aid for tertiary medical system
L&T keen on drainage project in Coimbatore
IOC to be sole supplier to Gujarat port SEZ
16.34-lakh LPG connections released under ``Deepam Scheme''
Drug cos seek `clarity' in Patent Act rules
3 IISc proteins for Cadila, Shantha Biotech
Kerala Govt warns erring KSEB officials
AP Govt steps up efforts to streamline power supply
Taxing problems
Draft Bill seeks to set up board for small sector
Karnataka SSIs plead against monthly payment of interest
Construction majors expected at Excon
`Reduce fee for regularisation of buildings'
Mumbai wholesalers' bandh tomorrow
Punjab gets down to disinvestment
USIBC team to explore scope in Kerala
ICFAI centre lead provider for European case club
Exhibition of Thai products
Hyderabad Engagements
1.63 lakh new I-T assessees in Karnataka, Goa
KUIDC to fund 2 tourism infrastructure projects
DCA expands probe into Xerox Modicorp — Moves CLB to look into fraudulent dealings
I-T Department conducts raids
Intelligence unit to check funding of terrorists


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2002, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line